Autor(es)

Barbosa, P. P. ; Leme, D. M. ; Motta, N. G. ; Magalhaes, W. L. E. ; Proenca-Modena, J. L. ; Maillard, J. -Y.

• Tipo de documento: Artigo Científico
• Fonte: Journal of Hospital Infection; v. 162, p. 9-pg., 2025-08-01.

Resumo

Background Staphylococcus aureus and Klebsiella pneumoniae are common pathogens responsible for hospital-acquired infections. Both species can survive on surfaces following desiccation and form dry surface biofilms (DSBs), which complicates the disinfection process. Aim To evaluate the efficacy of an innovative potassium monopersulphate-based nanotechnology formulation (MPS) against both planktonic and sessile S. aureus and K. pneumoniae. Methods The bactericidal efficacy of MPS was tested in comparison with sodium hypochlorite (NaOCl) and didecyldimethylammonium chloride (DDAC), which served as controls. The assessment was performed against planktonic bacteria, hydrated biofilm, and DSB using standard suspension and carrier tests. Scanning electron microscopy (SEM) was employed to identify any gross structural damage. Findings MPS (2% w/v) achieved a >= 4 log(10) reduction in K. pneumoniae with a short contact time, regardless of the test protocol. S. aureus was more resilient, but the introduction of wiping reduced the contact time needed to achieve a 4 log(10) reduction from 15 to 5 min. SEM analysis revealed gross structural damage in both species following MPS treatment. The other disinfectants tested were also bactericidal, achieving >= 4 log(10) reduction within 1-5 min, with the exception of DDAC against hydrated biofilms. Conclusion The potassium monopersulphate-based formulation was found to be an effective bactericide, including against DSBs. Its efficacy compares favourably with other biocides commonly used in healthcare settings, and its biodegradability makes it a promising candidate for further development. However, optimization of the mechanical removal process will be essential to enhance MPS efficacy in practical applications. (c) 2025 The Authors. Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). (AU)

• Processo FAPESP: 20/04558-0 - Caracterização de fatores de risco intrínsecos e o desenvolvimento de novas alternativas de diagnóstico e tratamento para COVID-19
• Beneficiário: José Luiz Proença Módena
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 16/00194-8 - Patogênese e neurovirulência de vírus emergentes no Brasil
• Beneficiário: José Luiz Proença Módena
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores